星汉德生物 Mediaroom - PR Newswire APAC

Search

星汉德生物

Latest News

SCG Cell Therapy Presents Promising Phase 1 Data for a Novel HBV-Specific TCR-T Therapy (SCG101) at the AASLD Liver Meeting 2024

SINGAPORE, Nov. 25, 2024 /PRNewswire/ -- SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechno...

2024-11-25 08:01 1217

SCG Cell Therapy Announces FDA IND Clearance of SCG142, a next-generation HPV-specific TCR T cell therapy for patients with HPV-associated solid tumors

SINGAPORE, July 1, 2024 /PRNewswire/ -- SCG Cell Therapy Pte Ltd (SCG), a biotechnology company dev...

2024-07-01 10:56 2018

Clinical Data of First-in-class HBV-specificTCR T Cell Therapy (SCG101) Presented at ESAL Congress Showing Improved Overall Survival in HBV-related Hepatocellular Carcinoma

SINGAPORE, June 7, 2024 /PRNewswire/ -- SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechno...

2024-06-07 16:51 2492

SCG Cell Therapy Presented New Preclinical Data in an Oral Presentation at ASGCT 2024 Annual Meeting Highlighting Superior Tumor Inhibition of its Immunoswitch Armored HPV-TCR T Cell Therapy (SCG142) against a Broad Range of HPV-associated Cancers

SINGAPORE, May 13, 2024 /PRNewswire/ -- SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnol...

2024-05-13 10:00 3232

SCG CELL THERAPY AND A*STAR LAUNCH JOINT LABS WITH COLLABORATION NEARING S$30 MILLION TO ADVANCE iPSC TECHNOLOGY TOWARDS SCALABLE GMP MANUFACTURING OF CELLULAR IMMUNOTHERAPIES

* Collaboration aims to develop scalable GMP-grade iPSC manufacturing processes and therapeutic c...

2024-04-17 10:00 1942

SCG CELL THERAPY AND A*STAR LAUNCH JOINT LABS WITH COLLABORATION NEARING S$30 MILLION TO ADVANCE iPSC TECHNOLOGY TOWARDS SCALABLE GMP MANUFACTURING OF CELLULAR IMMUNOTHERAPIES

SCG Cell Therapy Announces Late-Breaking Clinical Data at AASLD Showing SCG101 Improved Tumor Reponses and Achieved Sustained Antiviral Activates in Patients with Advanced HBV-related Hepatocellular Carcinoma

SINGAPORE, Nov. 14, 2023 /PRNewswire/ -- SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechno...

2023-11-14 02:00 2873

Significantly Reduce Manufacturing Cost and Increased Local Production: SCG Cell Therapy Opens State-of-the-art Cell Therapy Manufacturing Facility and R&D Centre in Singapore

* SCG Cell Therapy celebrates the opening of its new Cell Therapy Manufacturing Facility and R&D ...

2023-07-19 19:20 3535

Significantly Reduce Manufacturing Cost and Increased Local Production: SCG Cell Therapy Opens State-of-the-art Cell Therapy Manufacturing Facility and R&D Centre in Singapore

Best Presentation Award at EASL Congress 2023: First-in-class Bispecific Antibodies Anti-HBs×CD3 and Anti-HBs×CD28 Showed Strong Preclinical Efficacy in HBV Cure

SINGAPORE, July 12, 2023 /PRNewswire/ -- SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechno...

2023-07-12 18:13 2860

Best Presentation Award at EASL Congress 2023: First-in-class Bispecific Antibodies Anti-HBs×CD3 and Anti-HBs×CD28 Showed Strong Preclinical Efficacy in HBV Cure

SCG Cell Therapy Announces U.S FDA Clearance of Investigational New Drug Application for SCG101, SCG's Novel TCR-T Cell Therapy For Hepatitis B-related Liver Cancers

SINGAPORE, July 11, 2022 /PRNewswire/ -- Singapore-based SCG Cell Therapy Pte Ltd ("SCG") announced...

2022-07-11 13:34 2551

SCG Cell Therapy Presents Clinical Proof-of-Concept Data at International Liver Congress (ILC) 2022 Annual Meeting

* Clinical trial interim results of SCG101 shows tumour control with lesion shrinkage observed in...

2022-06-23 17:11 1988

SCG Cell Therapy announces clinical trial approval of TCR-T cell therapy for liver cancer in Singapore

*SCG101 - autologous T-cell receptor (TCR) T-cell therapy for liver cancer *SCG101 is the first TCR...

2022-05-09 10:28 3713

NMPA Clears IND for First T-Cell Receptor (TCR) T Cell Therapy to Treat Hepatitis B virus (HBV) associated hepatocellular carcinoma (HCC)

SINGAPORE, March 11, 2022 /PRNewswire/ -- Singapore-based SCG Cell Therapy Pte Ltd ("SCG"), a leadi...

2022-03-11 21:07 4964